Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study - Pierga, J Y; Petit, T; Delozier, T (Lancet Oncol, 2012)
et al